Tag Archives: Lilly

Federal Circuit Throws a Wrench into “Mechanism of Action” Claims

A three-judge panel of the Court of Appeals for the Federal Circuit recently decided Ariad Pharmaceuticals, Inc. et al. v. Eli Lilly & Company, appeal no. 2008-1248 (Fed. Cir. April 3, 2009), involving Blatimore et al. (U.S. Pat. No. 6,410,516). … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , | Leave a comment